[HTML][HTML] Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
J Baselga, J Cortés, SB Kim, SA Im… - … England Journal of …, 2012 - Mass Medical Soc
Background The anti–human epidermal growth factor receptor 2 (HER2) humanized monoclonal
antibody trastuzumab improves the outcome in patients with HER2-positive metastatic …
antibody trastuzumab improves the outcome in patients with HER2-positive metastatic …
[HTML][HTML] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
…, J Wolter, M Pegram, J Baselga… - New England journal …, 2001 - Mass Medical Soc
Background The HER2 gene, which encodes the growth factor receptor HER2, is amplified
and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the …
and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the …
[HTML][HTML] Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer
J Baselga, M Campone, M Piccart… - … England Journal of …, 2012 - Mass Medical Soc
Background Resistance to endocrine therapy in breast cancer is associated with activation of
the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies…
the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies…
A view on drug resistance in cancer
The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …
approach to define and separate the key determinants of drug resistance, which include …
[HTML][HTML] Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed …
J Baselga, KA Gelmon, S Verma… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Pertuzumab, a human epidermal growth factor receptor 2 (HER2)–targeted monoclonal
antibody, potently inhibits HER2 dimerization and HER-mediated signaling pathways. …
antibody, potently inhibits HER2 dimerization and HER-mediated signaling pathways. …
Epidermal growth factor receptor mutations and gene amplification in non–small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials
…, M Fukuoka, MG Kris, J Baselga… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Most cases of non–small-cell lung cancer (NSCLC) with dramatic responses to
gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR), but …
gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR), but …
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
…, EJ Coffman, CH Benes, HL Gómez, J Baselga… - Cancer discovery, 2011 - AACR
Cancers with specific genetic mutations are susceptible to selective kinase inhibitors.
However, there is a wide spectrum of benefit among cancers harboring the same sensitizing …
However, there is a wide spectrum of benefit among cancers harboring the same sensitizing …
The landscape of somatic copy-number alteration across human cancers
…, JE Tepper, JA Fletcher, J Tabernero, J Baselga… - Nature, 2010 - nature.com
A powerful way to discover key genes with causal roles in oncogenesis is to identify
genomic regions that undergo frequent alteration in human cancers. Here we present high-…
genomic regions that undergo frequent alteration in human cancers. Here we present high-…
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
J Baselga, I Bradbury, H Eidtmann, S Di Cosimo… - The Lancet, 2012 - thelancet.com
Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor
lapatinib have complementary mechanisms of action and synergistic antitumour activity …
lapatinib have complementary mechanisms of action and synergistic antitumour activity …
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Seventy percent of breast cancers express estrogen receptor (ER), and most of these are
sensitive to ER inhibition. However, many such tumors for unknown reasons become refractory …
sensitive to ER inhibition. However, many such tumors for unknown reasons become refractory …